Use of hiPSC-Derived Cardiomyocytes to Rule Out Proarrhythmic Effects of Drugs: The Case of Hydroxychloroquine in COVID-19
Description
This work was supported by the Marie Skłodowska-Curie Individual Fellowship (H2020-MSCA-IF-2017 No. 795209) to LS, the Fondazione CARIPLO, "Biomedical Research Conducted by Young Researchers" (Grant No. 2019-1691) to LS, the Leducq Foundation for Cardiovascular Research [18CVD05] "Toward Precision Medicine with Human iPSCs for Cardiac Channelopathies" to PS, MG, LC, LS, MM, the Ph.D. fellowship from the University of Verona to VL, the DZHK and the German Research Foundation Transregio Research Units 152 and 267 to AM.
Resources
| Name |
Format |
Description |
Link |
|
0 |
|
http://data.europa.eu/88u/dataset/oai-zenodo-org-7546567 |
Tags
- human-pluripotent-stem-cells;-cardiac-arrhythmias;-safety-pharmacology,-long-qt-syndrome,-hydroxychloroquine